Evidence map›Paper›PMID 40964677›Full record

ArticleFrontiers in microbiology2025

Protective effects of

Si-Pu Wang, Ling Ba, Xin-Rui Lv, Ya-Xin Qi, Xu Wang, Jie Zhang, Xin Xu

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Foods (Basel, Switzerland) · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Si-Pu Wang *Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China.
Ling Ba *Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China.
Xin-Rui Lv *Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China.
Ya-Xin QiDepartment of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China.
Xu WangDepartment of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China.
Jie ZhangDepartment of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China.
Xin XuDepartment of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The regenerating gene 3γ (Reg IIIγ) protein, a key antimicrobial peptide, is essential for maintaining intestinal barrier homeostasis and host defense. Its expression is impaired in metabolic-associated fatty liver disease (MAFLD), particularly under high-fat diet (HFD) conditions, contributing to barrier dysfunction. Given evidence that probiotic-derived components can modulate Reg IIIγ, this study aimed to evaluate the effects of Methods: Six-week-old C57BL/6 J mice were randomly assigned to four groups: standard diet with phosphate-buffered saline (PBS), standard diet with LGGs, high-fat diet (HFD) with PBS, and HFD with LGG. The expression of intestinal Reg IIIγ, changes in intestinal microbiota, and intestinal permeability were analyzed using quantitative PCR (qPCR) and western blot techniques. Results: HFD impaired the intestinal barrier in mice. However, oral administration of LGG significantly enhanced the expression of Reg IIIγ in the intestinal mucosa compared to control groups. This intervention notably improved intestinal barrier function, modulated the composition of intestinal microbiota, and mitigated MAFLD. Furthermore, an inverse correlation was observed between intestinal permeability and Reg IIIγ expression. Conclusion: LGG supernatant enhances intestinal Reg IIIγ expression through the MyD88/pSTAT3 signaling pathway, thereby contributing to the protection of intestinal barrier function and alleviation of MAFLD.

Indexed as

antimicrobial peptideintestinal barrierLactobacillus rhamnosus GGMAFLDReg IIIγ

Identifiers

PMID40964677
PMCPMC12436380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.